| __timestamp | Eli Lilly and Company | Merck & Co., Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 6620800000 | 11606000000 |
| Thursday, January 1, 2015 | 6533000000 | 10313000000 |
| Friday, January 1, 2016 | 6452000000 | 9762000000 |
| Sunday, January 1, 2017 | 6588100000 | 9830000000 |
| Monday, January 1, 2018 | 5975100000 | 10102000000 |
| Tuesday, January 1, 2019 | 6213800000 | 10615000000 |
| Wednesday, January 1, 2020 | 6121200000 | 8955000000 |
| Friday, January 1, 2021 | 6431600000 | 9634000000 |
| Saturday, January 1, 2022 | 6440400000 | 10042000000 |
| Sunday, January 1, 2023 | 6941200000 | 10504000000 |
| Monday, January 1, 2024 | 8593800000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical industry, operational efficiency is key. Over the past decade, Eli Lilly and Merck have demonstrated contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Eli Lilly's SG&A expenses have shown a modest increase of approximately 5%, peaking in 2023. In contrast, Merck's expenses have fluctuated more significantly, with a notable 23% drop from 2014 to 2020, before rebounding by 17% in 2023.
These trends highlight the strategic differences in managing operational costs, offering insights into each company's approach to maintaining competitive advantage.
Comparing SG&A Expenses: Eli Lilly and Company vs argenx SE Trends and Insights
Comparing SG&A Expenses: Eli Lilly and Company vs Halozyme Therapeutics, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Amneal Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Perrigo Company plc
Eli Lilly and Company and Wave Life Sciences Ltd.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing AbbVie Inc. and Merck & Co., Inc.
Selling, General, and Administrative Costs: Merck & Co., Inc. vs Sanofi
Cost Management Insights: SG&A Expenses for Merck & Co., Inc. and Alnylam Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Pharming Group N.V.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Catalyst Pharmaceuticals, Inc.
Merck & Co., Inc. and Novavax, Inc.: SG&A Spending Patterns Compared